A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis

Trial Profile

A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Tocilizumab (Primary) ; Tocilizumab (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SUMMACTA
  • Sponsors Roche
  • Most Recent Events

    • 17 Jun 2017 Results comparing the efficacy of subcutaneous tocilizumab with placebo or intravenous tocilizumab + csDMARDs for improvement in patient-reported outcomes in two randomized controlled trial populations (BREVACTA and SUMMACTA), presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Sep 2016 Results of pharmacokinetic and pharmacodynamic analysis from SUMMACTA and BREVACTA studies published in the Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top